| 영문 | Paget's disease | 한글 | 파제트병 |
|---|---|---|---|
| 설명 | 1. 뼈파제트병. 변형성 뼈염. 뼈흡수 후 뼈형성이 반복적으로 과도하게 일어나는 것으로, 새롭게 형성된 뼈는 무질서하고 구조적으로 견고하지 못하다. 뼈흡수의 증가가 반복되고 이어서 과잉보수를 꾀하여 약하고 변형된 뼈의 부피가 증가되는 것을 특징으로 하는 뼈병이다. 궁둥뼈의 만곡, 편평뼈의 변형을 일으키고, 동통 및 병적 골절을 수반한다. 2. 유방파제트병. 젖꽃판 및 젖꼭지의 염증성 암성 질병으로서 보통은 젖샘 및 유방 깊은 곳의 암을 동반한다. 보통 중년부인에게 발생한다. |
||
| 영문 | Parkinson disease | 한글 | 파킨슨병 |
|---|---|---|---|
| 설명 | 나이든 사람에게 발생하는 신경계의 퇴행병이다. 주로 운동을 담당하는 중간뇌부위가 침범된다. 원인은 바이러스, 약물, 혹은 동맥경화증 등으로 알려진 경우도 있으나, 원인을 알 수 없는 경우가 많다. 증상은 가면얼굴, 쓰러질 것 같은 걸음걸이, 손떨림, 근육의 강직, 앞으로 기울어진 자세 등임. 치료는 특별한 것이 없으며, 대개 보존적 치료(완치를 목적으로 하지 않고 단지 환자의 생활을 보조해주는 정도의 치료)를 시행한다. 최근, 죽은 태아의 뇌를 이식하는 뇌 이식술에 의한 치료효과가 높다는 보고가 있다. |
||
| 영문 | endemic disease | 한글 | 풍토병 |
|---|---|---|---|
| 설명 | 인간사회에 항상 존재하지만 특수한 기후나 토질로 인하여 특정지역에만 존재하는 사망률이 낮고, 임상적으로도 드물게 볼 수 있는 병. 특히 그 토지의 풍토-기후-생물-토양 등의 자연환경과 그 지방 주민의 풍속-습관-인습 등이 복잡하게 얽혀서 생긴 특수한 병을 가리킨다. 일반적으로 그 지방 주민의 사망률은 그다지 높지 않지만 근절되기 어려운 것이 특징이다. 지방병이라는 말은 어느 지방에 한정하여 볼 수 있는 병이라는 점에서는 같지만, 풍토환경과 밀접한 관계가 있다는 데서 보면 풍토병이라는 용어가 적절하다. 국내적으로는 쯔쯔가무시병, 야생토끼병, 렙토스피라증 등이 알려져 있고, 세계적으로는 말라리아, 황열, 페트스, 일본주혈흡충증 등이 알려져 있다. |
||
| 영문 | Hodgkin's disease | 한글 | 호지킨병 |
|---|---|---|---|
| 설명 | 악성림프종의 한 형태이다. 호지킨병은 방사선 치료에 대단히 예민해서 충분한 양의 방사선으로 완전한 근치적 치료가 가능하다. |
||
| GD | gastroduodenal; Gaucher disease; general diagnostics; general dispensary; gestational day; Gianotti ... |
|---|---|
| ICD | I-cell disease; immune complex disease; implantable cardioverter defibrillator; impulse-control diso... |
| ID | identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ... |
| ILD | interstitial lung disease; intraoperative localization device; ischemic leg disease; ischemic limb d... |
| LD | labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear... |
| drug, tocolytic | A medication that can inhibit labour, slow down or halt the contractions of the uterus. Tocolytic agents are widely used today to treat premature labour and permit pregnancy to procede and so permit the foetus to gain in size and maturity before being born. (12 Dec 1998) |
|---|---|
| drug tolerance | Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from drug resistance wherein a human, animal, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. (12 Dec 1998) |
| drug toxicity | The systemic effects of a drug that are related to the overall level of the medication in the bloodstream. Drug toxicity may occur with overdosage of a medication, accumulation of the drug in the body over time or the inability of the patients body to eliminate the drug. (27 Sep 1997) |
| drug utilization | The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles. (12 Dec 1998) |
| drug utilization review | Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for medicaid programs beginning in 1993. (12 Dec 1998) |
| drug withdrawal | A clinical syndrome of psychological, and, sometimes physical factors that result from the sustained use of a particular drug when the drug is abruptly withdrawn. Symptoms are variable but may include anxiety, nervousness, irritability, sweating, nausea, vomiting, rapid heart rate, rapid breathing and seizures. (27 Sep 1997) |
| dyskinesia, drug-induced | Abnormal movements induced as an adverse reaction of drug therapy. One particular movement disorder is the "on-off" effect. Tardive dyskinesia differs from akathisia, drug-induced in the repetitive nature of the movements rather than being associated with anxiety, restlessness, and agitation found in akathisia. (12 Dec 1998) |
| instillation, drug | The administration of therapeutic agents drop by drop, as eye drops, ear drops, or nose drops. It is also administered into a body space or cavity through a catheter. It differs from irrigation in that the irrigate is removed within minutes, but the instillate is left in place. (12 Dec 1998) |
| investigational new drug | Status given an experimental drug after the FDA approves an application for testing it in people. (09 Oct 1997) |
| investigational new drug application | An application that must be submitted to a regulatory agency (the FDA in the united states) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured. (12 Dec 1998) |
| orphan drug | A pharmaceutical that has been abandoned or neglected during its development because it is seen as having only a limited potential for profit. Often a drug which only has a limited target population or which treats a rare disease, thus limiting its financial potential. (09 Oct 1997) |
| orphan drug act | Law giving incentives to companies developing a drug for a rare disease. The act gives the developer of the first drug of any one type a 7-year exclusive right to market the new drug. (14 Nov 1997) |
| orphan drug production | Production of drugs or biologicals which are unlikely to be manufactured by private industry unless special incentives are provided by others. (12 Dec 1998) |
| targeted drug delivery | Delivering a drug to a specific site in the body where it has the greatest effect, instead of allowing it to diffuse to various sites, where it may cause damage or trigger side effects. (14 Nov 1997) |
| united states food and drug administration | An agency of the public health service concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc. (12 Dec 1998) |